| Target Price | $201.96 |
| Price | $185.96 |
| Potential |
8.60%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Quest Diagnostics 2026 .
The average Quest Diagnostics target price is $201.96.
This is
8.60%
register free of charge
$225.75
21.40%
register free of charge
$171.03
8.03%
register free of charge
|
|
| A rating was issued by 24 analysts: 12 Analysts recommend Quest Diagnostics to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Quest Diagnostics stock has an average upside potential 2026 of
8.60%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 9.87 | 11.09 |
| 6.70% | 12.37% | |
| EBITDA Margin | 15.55% | 19.75% |
| 1.03% | 27.02% | |
| Net Margin | 8.77% | 9.91% |
| 4.52% | 12.97% |
21 Analysts have issued a sales forecast Quest Diagnostics 2025 . The average Quest Diagnostics sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Quest Diagnostics EBITDA forecast 2025. The average Quest Diagnostics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Quest Diagnostics Analysts have issued a net profit forecast 2025. The average Quest Diagnostics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 7.66 | 9.90 |
| 1.86% | 29.24% | |
| P/E | 18.78 | |
| EV/Sales | 2.34 |
21 Analysts have issued a Quest Diagnostics forecast for earnings per share. The average Quest Diagnostics EPS is
This results in the following potential growth metrics and future valuations:
Quest Diagnostics...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Oct 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


